| . | OS Without Controlling for Tumor Size . | OS Controlling for Tumor Size . | ||
|---|---|---|---|---|
| Overall Survival, Tumor 2D . | Overall Survival, Tumor 3D . | |||
| . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | |
| Age at Treatment Initiation | 1.022 (1.006-1.039), P = .007 | 1.031 (1.013-1.049), P < .001 | 1.024 (1.005-1.043), P = .012 | |
| KPS at First Recurrent Treatment | <70 | Reference | Reference | Reference |
| ≥70 | 0.552 (0.341-0.893), P = .016 | 0.487 (0.289-0.820), P = .007 | 0.550 (0.319-0.949), P = .032 | |
| Treatment Group | CCNU 01-04 | Reference | Reference | Reference |
| Bev | 0.803 (0.489-1.320), P = .387 | 0.482 (0.269-0.864), P = .014 | 0.584 (0.336-1.016), P = .057 | |
| Bev/CCNU | 0.748 (0.462-1.212), P = .238 | 0.478 (0.273-0.837), P = .010 | 0.538 (0.316-0.916), P = .023 | |
| CCNU 09-15 | 0.305 (0.174-0.535), P < .001 | 0.235 (0.129-0.431), P < .001 | 0.253 (0.136-0.471), P < .001 | |
| Tumor Measurement | High | Reference | Reference | |
| Low | 0.623 (0.419-0.924), P = .019 | 0.711 (0.484-1.046), P = .083 | ||
| . | OS Without Controlling for Tumor Size . | OS Controlling for Tumor Size . | ||
|---|---|---|---|---|
| Overall Survival, Tumor 2D . | Overall Survival, Tumor 3D . | |||
| . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | |
| Age at Treatment Initiation | 1.022 (1.006-1.039), P = .007 | 1.031 (1.013-1.049), P < .001 | 1.024 (1.005-1.043), P = .012 | |
| KPS at First Recurrent Treatment | <70 | Reference | Reference | Reference |
| ≥70 | 0.552 (0.341-0.893), P = .016 | 0.487 (0.289-0.820), P = .007 | 0.550 (0.319-0.949), P = .032 | |
| Treatment Group | CCNU 01-04 | Reference | Reference | Reference |
| Bev | 0.803 (0.489-1.320), P = .387 | 0.482 (0.269-0.864), P = .014 | 0.584 (0.336-1.016), P = .057 | |
| Bev/CCNU | 0.748 (0.462-1.212), P = .238 | 0.478 (0.273-0.837), P = .010 | 0.538 (0.316-0.916), P = .023 | |
| CCNU 09-15 | 0.305 (0.174-0.535), P < .001 | 0.235 (0.129-0.431), P < .001 | 0.253 (0.136-0.471), P < .001 | |
| Tumor Measurement | High | Reference | Reference | |
| Low | 0.623 (0.419-0.924), P = .019 | 0.711 (0.484-1.046), P = .083 | ||
Abbreviations: 2D, 2-dimensional; 3D, 3-dimensional; Bev, bevacizumab; CI, confidence interval; CCNU, lomustine; OS, overall survival; KPS, Karnofsky Performance Status.
| . | OS Without Controlling for Tumor Size . | OS Controlling for Tumor Size . | ||
|---|---|---|---|---|
| Overall Survival, Tumor 2D . | Overall Survival, Tumor 3D . | |||
| . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | |
| Age at Treatment Initiation | 1.022 (1.006-1.039), P = .007 | 1.031 (1.013-1.049), P < .001 | 1.024 (1.005-1.043), P = .012 | |
| KPS at First Recurrent Treatment | <70 | Reference | Reference | Reference |
| ≥70 | 0.552 (0.341-0.893), P = .016 | 0.487 (0.289-0.820), P = .007 | 0.550 (0.319-0.949), P = .032 | |
| Treatment Group | CCNU 01-04 | Reference | Reference | Reference |
| Bev | 0.803 (0.489-1.320), P = .387 | 0.482 (0.269-0.864), P = .014 | 0.584 (0.336-1.016), P = .057 | |
| Bev/CCNU | 0.748 (0.462-1.212), P = .238 | 0.478 (0.273-0.837), P = .010 | 0.538 (0.316-0.916), P = .023 | |
| CCNU 09-15 | 0.305 (0.174-0.535), P < .001 | 0.235 (0.129-0.431), P < .001 | 0.253 (0.136-0.471), P < .001 | |
| Tumor Measurement | High | Reference | Reference | |
| Low | 0.623 (0.419-0.924), P = .019 | 0.711 (0.484-1.046), P = .083 | ||
| . | OS Without Controlling for Tumor Size . | OS Controlling for Tumor Size . | ||
|---|---|---|---|---|
| Overall Survival, Tumor 2D . | Overall Survival, Tumor 3D . | |||
| . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | Hazard Ratio (95% CI), P Value . | |
| Age at Treatment Initiation | 1.022 (1.006-1.039), P = .007 | 1.031 (1.013-1.049), P < .001 | 1.024 (1.005-1.043), P = .012 | |
| KPS at First Recurrent Treatment | <70 | Reference | Reference | Reference |
| ≥70 | 0.552 (0.341-0.893), P = .016 | 0.487 (0.289-0.820), P = .007 | 0.550 (0.319-0.949), P = .032 | |
| Treatment Group | CCNU 01-04 | Reference | Reference | Reference |
| Bev | 0.803 (0.489-1.320), P = .387 | 0.482 (0.269-0.864), P = .014 | 0.584 (0.336-1.016), P = .057 | |
| Bev/CCNU | 0.748 (0.462-1.212), P = .238 | 0.478 (0.273-0.837), P = .010 | 0.538 (0.316-0.916), P = .023 | |
| CCNU 09-15 | 0.305 (0.174-0.535), P < .001 | 0.235 (0.129-0.431), P < .001 | 0.253 (0.136-0.471), P < .001 | |
| Tumor Measurement | High | Reference | Reference | |
| Low | 0.623 (0.419-0.924), P = .019 | 0.711 (0.484-1.046), P = .083 | ||
Abbreviations: 2D, 2-dimensional; 3D, 3-dimensional; Bev, bevacizumab; CI, confidence interval; CCNU, lomustine; OS, overall survival; KPS, Karnofsky Performance Status.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
